Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Free Cash Flow to Equity (FCFE) 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 19, 2024

Kalvista Pharmaceuticals Inc Free Cash Flow to Equity (FCFE) 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 19, 2024. Free Cash Flow to Equity represents the cash flow available to equity shareholders after accounting for capital expenditures and net acquisitions. It indicates the amount of cash flow that can be distributed to shareholders or reinvested in the business. It is useful in assessing the company's ability to generate cash flow for its equity investors. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends